29 July 2026
Brain tumour charities call for progress on research, treatment and support This month, we joined five other key organisations dedicated to helping the brain tumour community in writing a joint letter to the new Secretary of State for Health and…
Read
2 July 2026
Our Head of Support Services and CEO shared the importance of timely, personalised support for people affected by a brain tumour. Brain Tumour Support was delighted to attend BNOS 2026 in Birmingham this week, joining healthcare professionals, researchers, charities and…
Read
16 June 2026
Brain Tumour Support has welcomed the powerful and emotive discussions that took place in Parliament yesterday (Monday 15 June), as the urgent need for greater investment in brain cancer research and treatment was debated. Securing this debate was a notable…
Read
21 May 2026
When someone is diagnosed with a brain tumour, they may be overwhelmed by the need to understand a new language. This article aims to provide a shortcut to that new language so that patients, caregivers, colleagues, employers, journalists, policymakers and…
Read
31 March 2026
At Brain Tumour Support, we have been closely following developments around Vorasidenib, a targeted therapy that has shown promise for people living with certain types of low-grade glioma. So we are delighted to share today’s final decision by the National…
Read
10 March 2026
We are delighted to share that the Scottish Medicines Consortium (SMC) has approved Vorasidenib (Voranigo) for patients aged 12 and over with IDH-mutant low-grade gliomas, including grade 2 astrocytomas and oligodendrogliomas. This marks an important milestone for patients, families and…
Read
28 February 2026
This month marks a major milestone in the fight against rare cancers (those affecting fewer than 1 in 2000 people), including brain tumours, as the Rare Cancers Bill has successfully passed its Third Reading in the House of Lords and…
Read
26 February 2026
When we tell people that brain tumours are the biggest cancer killer of the under 40s, their first reaction is often shock or disbelief. What’s the evidence for this and where do we get our figures from?
Read
13 January 2026
We know that many people in our community are eagerly anticipating NICE’s decision on NHS funding for Vorasidenib. Yesterday, 12 January, it was announced that the appraisal for the drug has been paused, at the request of the drug’s manufacturer,…
Read
19 December 2025
Hope for our community as NIHR funding is invested to establish a new Brain Tumour Research Consortium The National Institute for Health and Care Research (NIHR) has today announced key funding which is a significant move towards better treatments and…
Read
14 November 2025
Bristol-based neuropathologist Professor Kathreena Kurian, who lost her husband Gerard to a brain tumour, is leading a national campaign to end postcode inequalities in brain tumour care with a newly released study into molecular and genetic testing of brain tumour patients….
Read
19 October 2025
Liam Vincent-Kilbride was diagnosed with a grade 2 glioma, and following surgery in October 2024 was offered to be part of the Early Access Program, taking Vorasidenib. After 10 months on the drug, he shared his experience and reaction in…
Read